Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
US11248027B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11248027-B2 |
| Application number | US-201715844753-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2017 |
| Priority date | Jun 17, 2015 |
| Publication date | Feb 15, 2022 |
| Grant date | Feb 15, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.
First claim
Opening claim text (preview).
What is claimed is: 1. A non-naturally occurring protein comprising a monomeric engineered outer domain (eOD), wherein the protein comprises SEQ ID NO: 10 (eOD-GT8). 2. The protein according to claim 1 , further comprising a tag for purification or biotinylation. 3. The protein according to claim 2 , wherein the tag for purification is a his tag. 4. The protein according to claim 2 , wherein the tag for biotinylation is an avi-tag. 5. The protein according to claim 1 , further comprising an additional cysteine, whereby the cysteine is configured for chemical conjugation.
Assignees
Inventors
Classifications
transferring alkyl or aryl groups other than methyl groups (2.5) · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
6,7-Dimethyl-8-ribityllumazine synthase (2.5.1.78) · CPC title
Murine · CPC title
Knock-in vertebrates, e.g. humanised vertebrates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11248027B2 cover?
- The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broa…
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative, Scripps Research Inst
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).